20/20 BIOLABS, INC.

20/20 Biolabs, Inc. develops and sells AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The company offers two families of lab tests under its OneTest brand: OneTest for Cancer, a multi-cancer early detection (MCED) test, and OneTest for Longevity, which measures inflammatory biomarkers. OneTest for Longevity was launched in February 2026 and is also branded "OneTest for Workplace Wellness" when marketed to self-insured employers. Both tests are processed in the company's CAP (College of American Pathologists) accredited, CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory located in Gaithersburg, MD. This laboratory also houses the Clinical Laboratory Innovation Accelerator (CLIAx), which is a shared CLIA laboratory for overseas diagnostics start-ups. The company's legacy business includes BioCheck, a field test kit for screening suspicious powders for bioterror agents. For the year ended December 31, 2025, sales of OneTest for Cancer accounted for approximately 88% of revenues, BioCheck accounted for approximately 8% of revenues, and CLIAx accounted for approximately 4% of revenues. For the year ended December 31, 2024, sales of OneTest for Cancer accounted for approximately 85% of revenues, BioCheck accounted for approximately 10% of revenues, and CLIAx accounted for approximately 5% of revenues. The company was incorporated in Delaware on August 7, 2000, as 20/20 BioSystems, Inc., and subsequently changed its name to 20/20 Gene Systems, Inc. on September 19, 2000, to 20/20 GeneSystems, Inc. on June 27, 2021, and to 20/20 Biolabs, Inc. on March 19, 2025. The company does not have any subsidiaries.